Shandong lukang pharmaceutical Co.,Ltd
Shandong Lukang has a total asset of RMB 6.6 billion and more than 6,000 employees. The company owns 13 joint ownership enterprises, including 5 wholly-owned subsidiaries, 6 holding companies and 2 joint ventures. Qinghai Lukang Dadi company is the production base of Chinese traditional medicine and Tibetan traditional medicine, Shandong Lukang Saite company is the production base of Non Penicillin and Non-Cephalosporin FDFs, and Shandong Lukang Biological Pesticides company is the production base of Agricultural Chemical.
Lukang Pharma is specialized in manufacturing APIs for both human and veterinary use , FDFs for Human Use and Agricultural Chemical, and supplies a total of over 500 types of product, such anti-infective, cardiovascular and cerebrovascular drug, diabetes drug and amino acids product. The company has an annual production capacity of 150,000 tons of kinds of APIs, 6 billion tablets/capsules /bags of oral solid FDFs, and 2 billion vials of powder for injection. The company has passed ISO 9001, ISO 14001, and OHMS certifications. More than one product has passed US FDA inspection, more than one product got CEP certificates, and one product got EU GMP certificate. Lukang Pharma sells its product well all over the country, and as well as exports to 50 countries and regions across Asia, Europe, Africa and America, with $150 million of annual exports.
At present, Lukang Pharma has 4 National High-tech Enterprises, 1 State-level Enterprise Technology Center, 2 Provincial Enterprise Technology Center, 1 Shandong Province Engineering Technology Research Center, and has established academician workstation and post-doctoral scientific research workstation. Lukang Pharma is awarded as the "National Torch Plan Key High-tech Enterprise" and the first batch of "National Comprehensive New Drug Research and Development Technology Platform (Shandong) Industrialization Demonstration Enterprise". In 2017, Lukang Pharma established Shandong Provincial Biotechnology Industry Transform Platform together with Tianjin Institute of Chinese Academy of Sciences. In 2018, the Shandong brand international science and technology cooperation base was approved by Dept. of Science & Technology of Shandong Province, and Shandong University-Lukang Institute of Pharmaceutical Microbiology was established.
Many honorary titles such as "the Vice President Company of Chinese Pharmaceutical Industry Association and China Pharmaceutical Enterprises Association", "Top 100 Pharmaceutical Enterprises", "Top 100 Internationalized Pharmaceutical Enterprises", "National Advanced Enterprises in Both Quality and Efficiency", "Drug Quality Good Faith Construction Demonstration Enterprise", "National Medicine Excellent Enterprise", "National Customer Satisfaction Enterprise", "Ministry of Industry and Information Technology 'Integration of Two' Pilot Enterprise", "Benchmarking Enterprise in 40 Years of Reform and Opening-up" were successively awarded to the company. Besides, "Lukang" brand was praised as "the Export Brand Critically Cultivated and Developed by the Ministry of Commerce". In May 2019, the company was rated as a High-end Brand Cultivation Enterprise of Shandong Province; In July, selected as the first batch of Technological Innovation Demonstration Enterprises of Shandong Province.
New Era, New Lukang, New Dream, New future. It is the mission and unremitting pursuit of Lukang Pharma to keep people away from diseases and sufferings. With the continuous investment in park construction, new drug research and development, product structure adjustment, management improvement and other aspects, Lukang Pharma will achieve leap-forward and sustainable development with high-quality, and make greater contribution to human health.
